Enhacement of the lower extremities computed tomography: IOMERON®-400 VS VISIPAQUE™-320 (ELECTIV).
- Registry ID
- EUCTR2004-000712-42
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Bracco Imaging S.p.A.
- Start date
- 2004-12-22
- Last update
- 2026-08-16
Conditions
- PERIPHERAL VASCULAR DISEASE
- Patients with mild to moderate renal impairment who undergo clinically-indicated IV contrast-enhanced MDCTA (multi detector computed tomography angigraphy)scanning of the lower extremity arterial system, for suspected arterial disease, primarily narrowing or ischemia.
- subjects with mild to moderate renal impairment scheduled to undergo clinically-indicated IV contrast –enhanced MDCT scanning of the lower extremities.
- subjects with mild to moderate renal impairment (SCr =1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min) who undergo clinically-indicated IV contrast-enhanced MDCTA scanning of the lower extremity arterial system
Summary
·To quantitatively compare the efficacy of enhancement of key arteries in subjects with mild to moderate renal impairment (SCr =1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min) who undergo clinically-indicated IV contrast-enhanced MDCTA scanning of the lower extremity arterial system with equi-iodine doses of one of two contrast agents, Iomeron®-400 or Visipaque™-320.
Locations
- , , UK
- , , Italy
- , , Sweden
- , , Austria
View on source registry